Advertisement

Helicobacter pylori Infection: New Facts in Clinical Management

  • Peter Malfertheiner
  • Marino Venerito
  • Christian Schulz
Stomach (P Malfertheiner, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Stomach

Abstract

Purpose

The global prevalence of Helicobacter pylori remains high in spite of its significant downwards trajectory in many regions. The clinical management of H. pylori infection merits guidance to meet ongoing challenges on whom and how to test, prevent, and cure related diseases.

Recent findings

Several international guidelines and consensus reports have updated the management strategies for cure of the H. pylori infection. The definition of H. pylori gastritis as an infectious disease independent of whether or not presenting with clinical manifestations and symptoms has broadened the use of the test and treat strategy. Patients on selected long-term medications, such as aspirin, other anti-platelet agents, NSAIDs, and PPIs should be considered for H. pylori test and treat. Important progress is made with initiatives in primary and secondary gastric cancer prevention. Uncertainties persist in the interpretation of the role of H. pylori in association with extragastric diseases. Selection of therapies needs to address individual antibiotic resistance and regional surveillance of resistance for the adoption of an effective treatment algorithm.

Conclusion

Clinical aspects of H. pylori infection have evolved over time and the therapeutic management requires continuous adaptation. A vaccine is still a non-fulfilled promise. The future will tell us more about the role of H. pylori in interactions with the gut microbiome.

Keywords

Helicobacter pylori Stomach H. pylori Microbiome Gastritis Test & treat Antibiotic resistance 

Notes

Compliance with Ethical Standards

Conflict of Interest

Peter Malfertheiner is involved in speakers bureau/or consulting: Biocodex, Biohit, Danone, Mayoly- Spindler. Marino Venerito declares that he has no conflict of interest. Christian Schulz declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as • Of importance •• Of major importance

  1. 1.
    Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–9.  https://doi.org/10.1053/j.gastro.2017.04.022.CrossRefPubMedGoogle Scholar
  2. 2.
    Franck C, Hoffmann A, Link A, et al. Prevalence of Helicobacter pylori infection among blood donors in Saxony-Anhalt, Germany - a region at intermediate risk for gastric Cancer. Z Gastroenterol. 2017;55 (7) ,653-656.CrossRefGoogle Scholar
  3. 3.
    Venneman K, Huybrechts I, Gunter MJ, Vandendaele L, Herrero R, Van Herck K. The epidemiology of Helicobacter pylori infection in Europe and the impact of lifestyle on its natural evolution toward stomach cancer after infection: a systematic review. Helicobacter. 2018;23(3):e12483.  https://doi.org/10.1111/hel.12483.CrossRefPubMedGoogle Scholar
  4. 4.
    Wang C, Nishiyama T, Kikuchi S, et al. Changing trends in the prevalence of H. pylori infection in Japan (1908–2003): a systematic review and meta-regression analysis of 170,752 individuals. Sci Rep. 2017;7(1):1–12.  https://doi.org/10.1038/s41598-017-15490-7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    • Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212–39.  https://doi.org/10.1038/ajg.2016.563 Provides a comprehensive insight in clinical developments of H. pylori infection with recommendations for management with focus on practice in US.CrossRefPubMedGoogle Scholar
  6. 6.
    • Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51–69.e14.  https://doi.org/10.1053/j.gastro.2016.04.006 Thourough assessment of available and recommended eradication therapies.CrossRefPubMedGoogle Scholar
  7. 7.
    • Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2016;66(1):6–30.  https://doi.org/10.1136/gutjnl-2016-312288 Update on all clinical aspects related to H. pylori infection includung future directions concerning screen and treat strategies, update on treatment recommendations and adressing the new focus on gastric microbiota beyond H. pylori.CrossRefPubMedGoogle Scholar
  8. 8.
    • Mahachai V, Vilaichone R, Pittayanon R, et al. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018;33(1):37–56.  https://doi.org/10.1111/jgh.13911 Focus on clinical aspects of H. pylori infection in Asia and recommendations for clinical managment.CrossRefPubMedGoogle Scholar
  9. 9.
    Ražuka-Ebela D, Bianca Giupponi FF. The year in Helicobacter. Helicobacter. 2018.Google Scholar
  10. 10.
    Egeberg A, Weinstock LB, Thyssen EP, Gislason GH, Thyssen JP. Rosacea and gastrointestinal disorders: a population-based cohort study. Br J Dermatol. 2017;176(1):100–6.  https://doi.org/10.1111/bjd.14930.CrossRefPubMedGoogle Scholar
  11. 11.
    Hou Y, Sun W, Zhang C, et al. Meta-analysis of the correlation between Helicobacter pylori infection and autoimmune thyroid diseases. Oncotarget. 2017;8(70):115691–700.  https://doi.org/10.18632/oncotarget.22929.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Von Arnim U, Wex T, Link A, et al. Helicobacter pylori infection is associated with a reduced risk of developing eosinophilic oesophagitis. Aliment Pharmacol Ther. 2016;43(7).  https://doi.org/10.1111/apt.13560.CrossRefGoogle Scholar
  13. 13.
    Molina-Infante J, Gutierrez-Junquera C, Savarino E, et al. Helicobacter pylori infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study. Am J Gastroenterol. 2018;113(7):972–9.  https://doi.org/10.1038/s41395-018-0035-6.CrossRefPubMedGoogle Scholar
  14. 14.
    Arnold IC, Hitzler I, Müller A. The immunomodulatory properties of Helicobacter pylori confer protection against allergic and chronic inflammatory disorders. Front Cell Infect Microbiol. 2012;2:10.  https://doi.org/10.3389/fcimb.2012.00010.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lionetti E, Leonardi S, Lanzafame A, Garozzo MT, Filippelli M, Tomarchio S, et al. Helicobacter pylori infection and atopic diseases: is there a relationship? A systematic review and meta-analysis. World J Gastroenterol. 2014;20(46):17635–47.  https://doi.org/10.3748/wjg.v20.i46.17635.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    den Hollander WJ, Sonnenschein-van der Voort AMM, Holster IL, et al. Helicobacter pylori in children with asthmatic conditions at school age, and their mothers. Aliment Pharmacol Ther. 2016;43(8):933–43.  https://doi.org/10.1111/apt.13572.CrossRefGoogle Scholar
  17. 17.
    Aniwan S, Tremaine WJ, Raffals LE, Kane SV, Loftus EV. Antibiotic use and new-onset inflammatory bowel disease in Olmsted county, Minnesota: a population-based case-control study. J Crohn’s Colitis. 2018;12(2):137–44.  https://doi.org/10.1093/ecco-jcc/jjx135.CrossRefGoogle Scholar
  18. 18.
    Rosania R, Arnim UV, Link A, et al. Helicobacter pylori eradication therapy is not associated with the onset of inflammatory bowel diseases. A case-control study. J Gastrointest Liver Dis. 2018;27(2).  https://doi.org/10.15403/jgld.2014.1121.272.hpy.
  19. 19.
    Sung JJ, Chiu PC, Chan FKL, et al. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Gut. 2018;67:1757–68.  https://doi.org/10.1136/gutjnl-2018-316276.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Chan FKL, Ching JYL, Suen BY, Tse YK, Wu JCY, Sung JJY. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology. 2013;144(3):528–35.  https://doi.org/10.1053/j.gastro.2012.12.038.CrossRefPubMedGoogle Scholar
  21. 21.
    Sostres C, Carrera-Lasfuentes P, Benito R, et al. Peptic ulcer bleeding risk. The role of Helicobacter pylori infection in NSAID/low-dose aspirin users. Am J Gastroenterol. 2015;110(5):684–9.  https://doi.org/10.1038/ajg.2015.98.CrossRefPubMedGoogle Scholar
  22. 22.
    Venerito M, Schneider C, Costanzo R, Breja R, Röhl FW, Malfertheiner P. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors. Aliment Pharmacol Ther. 2018;(December 2017).  https://doi.org/10.1111/apt.14652 CrossRefGoogle Scholar
  23. 23.
    Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3(4):231–41.  https://doi.org/10.1016/S2468-1253(18)30037-2.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):302–18.  https://doi.org/10.1053/j.gastro.2017.07.049.CrossRefPubMedGoogle Scholar
  25. 25.
    Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14(12):697–710.  https://doi.org/10.1038/nrgastro.2017.117.CrossRefPubMedGoogle Scholar
  26. 26.
    Poulsen AH, Christensen S, McLaughlin JK, et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. 2009;100(9):1503–7.  https://doi.org/10.1038/sj.bjc.6605024.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CDA. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(12):1706–1719.e5.  https://doi.org/10.1016/j.cgh.2016.05.018.CrossRefPubMedGoogle Scholar
  28. 28.
    Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori : a population-based study. Gut. 2017;gutjnl-2017-314605.  https://doi.org/10.1136/gutjnl-2017-314605 CrossRefGoogle Scholar
  29. 29.
    Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67(2):226–36.  https://doi.org/10.1136/gutjnl-2017-314205.CrossRefPubMedGoogle Scholar
  30. 30.
    Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–67.  https://doi.org/10.1136/gutjnl-2015-309252.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Lee Y-C, Chiang T-H, Chou C-K, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150(5):1113–1124.e5.  https://doi.org/10.1053/j.gastro.2016.01.028.CrossRefPubMedGoogle Scholar
  32. 32.
    Seta T, Takahashi Y, Noguchi Y, et al. Effectiveness of Helicobacter pylori eradication in the prevention of primary gastric cancer in healthy asymptomatic people: A systematic review and meta-analysis comparing risk ratio with risk difference. Katoh M, ed. PLoS One. 2017;12(8):e0183321.  https://doi.org/10.1371/journal.pone.0183321.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut. 2018;gutjnl-2017-315363.  https://doi.org/10.1136/gutjnl-2017-315363 CrossRefGoogle Scholar
  34. 34.
    •• Choi IJ, Kook M-C, Kim Y-I, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378(12):1085–95.  https://doi.org/10.1056/NEJMoa1708423 First randomized prospective controlled trial providing evidence that H. pylori eradication prevents the development of metachronous gastric cancer following the endoscopic removal of early gastic cancer in a significant proportion of patients; suggests that H. pylori eradication will always remain beneficial although less effective in advanced stage of chronic atrophic gastritis.CrossRefPubMedGoogle Scholar
  35. 35.
    Venerito M, Goni E, Malfertheiner P. Helicobacter pylori screening: options and challenges. Expert Rev Gastroenterol Hepatol. 2016;10(4).  https://doi.org/10.1586/17474124.2016.1126507 CrossRefGoogle Scholar
  36. 36.
    Malfertheiner P. Helicobacter pylori treatment for gastric cancer prevention. N Engl J Med. 2018;378(12):1154–6.  https://doi.org/10.1056/NEJMe1800147.CrossRefPubMedGoogle Scholar
  37. 37.
    Zagari RM, Rabitti S, Greenwood DC, Eusebi LH, Vestito A, Bazzoli F. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther. 2017;46(7):657–67.  https://doi.org/10.1111/apt.14248.CrossRefPubMedGoogle Scholar
  38. 38.
    Malfertheiner P. Editorial: the non-invasive diagnosis of atrophic gastritis. Aliment Pharmacol Ther. 2017;46(11–12):1112–3.  https://doi.org/10.1111/apt.14340.CrossRefPubMedGoogle Scholar
  39. 39.
    Hamashima C, Shabana M, Okada K, Okamoto M, Osaki Y. Mortality reduction from gastric cancer by endoscopic and radiographic screening. Cancer Sci. 2015;106(12):1744–9.  https://doi.org/10.1111/cas.12829.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Jun JK, Choi KS, Lee H-Y, et al. Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. Gastroenterology. 2017;152(6):1319–1328.e7.  https://doi.org/10.1053/j.gastro.2017.01.029.CrossRefPubMedGoogle Scholar
  41. 41.
    Song M, Camargo MC, Weinstein SJ, Murphy G, Freedman ND, Koshiol J, et al. Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males. Aliment Pharmacol Ther. 2018;47(4):494–503.  https://doi.org/10.1111/apt.14471.CrossRefPubMedGoogle Scholar
  42. 42.
    Venerito M, Vasapolli R, Theodoros Rokkas PM. Gastric cancer: epidemiology, prevention and therapy. Helicobacter. 2018;suppl.1 e12518.Google Scholar
  43. 43.
    Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43(10):1048–59.  https://doi.org/10.1111/apt.13588.CrossRefPubMedGoogle Scholar
  44. 44.
    Li M, Oshima T, Horikawa T, Tozawa K, Tomita T, Fukui H, et al. Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018;23(4):e12495.  https://doi.org/10.1111/hel.12495.CrossRefPubMedGoogle Scholar
  45. 45.
    Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti-Infect Ther. 2018;16:1–9.  https://doi.org/10.1080/14787210.2018.1511427.CrossRefGoogle Scholar
  46. 46.
    Malfertheiner P, Chan FK, EL McColl K. Peptic ulcer disease. Lancet. 2009;374(9699):1449–61.  https://doi.org/10.1016/S0140-6736(09)60938-7.CrossRefGoogle Scholar
  47. 47.
    Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013;88(1).  https://doi.org/10.1159/000350719 CrossRefGoogle Scholar
  48. 48.
    Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–27.  https://doi.org/10.1016/S1473-3099(17)30753-3.CrossRefPubMedGoogle Scholar
  49. 49.
    Gatta L, Scarpignato C, Fiorini G, Belsey J, Saracino IM, Ricci C, et al. Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther. 2018;47(9):1261–9.  https://doi.org/10.1111/apt.14597.CrossRefPubMedGoogle Scholar
  50. 50.
    Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514–33.  https://doi.org/10.1111/apt.13497.CrossRefPubMedGoogle Scholar
  51. 51.
    Ierardi E, Giorgio F, Iannone A, Losurdo G, Principi M, Barone M, et al. Noninvasive molecular analysis of Helicobacter pylori : is it time for tailored first-line therapy? World J Gastroenterol. 2017;23(14):2453–8.  https://doi.org/10.3748/wjg.v23.i14.2453.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Pastukh N, Binyamin D, On A, Paritsky M, Peretz A. GenoType® HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones. Helicobacter. 2017;22(6):e12447. https://doi.org/10.1111/hel.12447.CrossRefGoogle Scholar
  53. 53.
    Skrebinska S, Megraud F, Bessede F. Diagnosis of H.pylori. Helicobacter. 2018;23 suppl 1.  https://doi.org/10.1111/hel.12515 CrossRefGoogle Scholar
  54. 54.
    Lv Z, Wang B, Zhou X, et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med. 2015;9(3):707–16.  https://doi.org/10.3892/etm.2015.2174.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS One. 2014;9(11):e111030.  https://doi.org/10.1371/journal.pone.0111030.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    McFarland LV, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United Eur Gastroenterol J. 2016;4(4):546–61.  https://doi.org/10.1177/2050640615617358.CrossRefGoogle Scholar
  57. 57.
    Szajewska H, Shamir R, Chmielewska A, et al. Systematic review with meta-analysis: early infant feeding and coeliac disease–update 2015. Aliment Pharmacol Ther. 2015;41(11):1038–54.  https://doi.org/10.1111/apt.13163.CrossRefPubMedGoogle Scholar
  58. 58.
    McNicholl AG, Molina-Infante J, Lucendo AJ, et al. Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: a randomized, double-blind, placebo-controlled trial. Helicobacter. 2018;23:e12529.  https://doi.org/10.1111/hel.12529.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Peter Malfertheiner
    • 1
    • 2
  • Marino Venerito
    • 1
  • Christian Schulz
    • 2
  1. 1.Department of Gastroenterology, Hepatology and Infectious DiseasesOtto-von-Guericke University HospitalMagdeburgGermany
  2. 2.Department of Medicine IIUniversity Hospital, LMUMunichGermany

Personalised recommendations